While Aardvark Therapeutics Inc has overperformed by 6.86%, investors are advised to look at stock chart patterns for technical insight.
On March 10, 2025, RBC Capital Mkts started tracking Aardvark Therapeutics Inc (NASDAQ: AARD) recommending Outperform. A report published by Morgan Stanley on March 10, 2025, Initiated its previous ‘Overweight’ rating for AARD. Cantor Fitzgerald also rated AARD shares as ‘Overweight’, setting a target price of $50 on the company’s shares in an initiating report dated March 10, 2025. BofA Securities Initiated an Buy rating on March 10, 2025, and assigned a price target of $22.
Analysis of Aardvark Therapeutics Inc (AARD)
Aardvark Therapeutics Inc’s future performance can be predicted by a variety of well-rounded types of analysis and research, with equity being one of the most crucial ones. Taking into account the quick ratio of the company, currently set at 15.05, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can be an extremely valuable indicator of volatility, and AARD is registering an average volume of 185.03K. On a monthly basis, the volatility of the stock is set at 16.69%, whereas on a weekly basis, it is put at 24.63%, with a loss of -16.68% over the past seven days. Furthermore, long-term investors anticipate a median target price of $31.50, showing growth from the present price of $7.79, which can serve as yet another indication of whether AARD is worth investing in or should be passed over.
How Do You Analyze Aardvark Therapeutics Inc Shares?
Besides checking the fundamentals, you should also know how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 42.89%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 10.05% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
AARD shares are owned by institutional investors to the tune of 10.05% at present.
